- Home
- RGTIW vs SNY Comparison
RGTIW vs SNY Comparison
Compare RGTIW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGTIW | SNY |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 104.5B |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | RGTIW | SNY |
|---|---|---|
| Price | $7.06 | $42.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $58.00 |
| AVG Volume (30 Days) | 50.2K | ★ 2.0M |
| Earning Date | 03-11-2025 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.47% |
| EPS Growth | ★ 35.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,102,000.00 | N/A |
| Revenue This Year | N/A | $3.49 |
| Revenue Next Year | N/A | $6.10 |
| P/E Ratio | ★ N/A | $6.14 |
| Revenue Growth | ★ 59.86 | N/A |
| 52 Week Low | $4.61 | $40.89 |
| 52 Week High | $46.78 | $52.68 |
Technical Indicators
Market Signals| Indicator | RGTIW | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 39.80 |
| Support Level | $6.30 | $42.30 |
| Resistance Level | $6.99 | $45.22 |
| Average True Range (ATR) | 0.50 | 0.58 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 23.12 | 6.40 |
Price Performance
Historical ComparisonAbout RGTIW Rigetti Computing Inc.
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.